Enzene Receives Marketing Authorization for Romiplostim (biosimilar) in India

Shots:

DCGI has granted the marketing authorization to Enzene’s Romiplostim biosimilar for the treatment of chronic ITP in adults
The company provides all the three dosage strengths of the product (125mcg, 250mcg, and 500mcg)
Romiplostim is an Fc-peptide fusion protein that increases platelet production through activation of the thrombopoietin receptor. The company’s first biosimilar Teriparatide has been launched in early 2021 for the treatment of osteoporosis

Click here to read full press release/ article | Ref: PRnewswire | Image: Stat News